{"id":"NCT03334435","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis","officialTitle":"A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-28","primaryCompletion":"2020-09-21","completion":"2023-07-12","firstPosted":"2017-11-07","resultsPosted":"2022-07-01","lastUpdate":"2024-09-03"},"enrollment":1645,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Baricitinib","otherNames":["LY3009104"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Responders and Partial Responders (RPR)-Placebo","type":"PLACEBO_COMPARATOR"},{"label":"RPR-Bari 1-milligram (mg)","type":"EXPERIMENTAL"},{"label":"RPR-Bari 2-mg","type":"EXPERIMENTAL"},{"label":"RPR-Bari 4-mg","type":"EXPERIMENTAL"},{"label":"Non-responders (NR): Bari 1 mg to 2 mg","type":"EXPERIMENTAL"},{"label":"NR: Bari 1 mg to 4 mg","type":"EXPERIMENTAL"},{"label":"NR: Bari 2 mg to 2 mg","type":"EXPERIMENTAL"},{"label":"NR: Bari 2 mg to 4 mg","type":"EXPERIMENTAL"},{"label":"NR: Bari 4 mg to 4 mg","type":"EXPERIMENTAL"},{"label":"NR: Placebo to Bari 2 mg","type":"EXPERIMENTAL"},{"label":"NR: Placebo to Bari 4 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Bari 1 mg","type":"EXPERIMENTAL"},{"label":"Bari 2 mg","type":"EXPERIMENTAL"},{"label":"Bari 4 mg","type":"EXPERIMENTAL"},{"label":"Bari 2-mg Open-Label Addendum","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis.\n\nParticipants were enrolled in this study from the originating studies (JAHL, JAHM, JAIY) or were directly enrolled in the open-label arm.","primaryOutcome":{"measure":"Responder and Partial Responders (RPR): Percentage of Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of Investigator's Global Assessment (IGA) 0 or 1","timeFrame":"Weeks 16, 36 and 52","effectByArm":[{"arm":"RPR-Placebo","deltaMin":36.5,"sd":null},{"arm":"RPR-Bari 1-mg","deltaMin":46.7,"sd":null},{"arm":"RPR-Bari 2-mg","deltaMin":59.3,"sd":null},{"arm":"RPR-Bari 4-mg","deltaMin":48.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":185,"countries":["Argentina","Australia","Austria","Czechia","Denmark","France","Germany","Hungary","India","Israel","Italy","Japan","Mexico","Poland","Russia","South Korea","Spain","Switzerland","Taiwan"]},"refs":{"pmids":["36912484","36763879","36749121","36255569","33978711","33826132"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/64kocErmNim2YSiiqCaOk6"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":91},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Covid-19","Headache","Oral herpes"]}}